Related Experiment Video
Updated: Jun 27, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
Dilated Cardiomyopathy
1Division of Cardiology, Heart-Lung Research Institute, The Ohio State University Medical Center, 473 West 12th Avenue, Room 261, Columbus, OH 43210, USA. Leier.1@osu.edu
Insights
Managing dilated cardiomyopathy (DCM) heart failure involves diagnosing the cause, assessing heart function, and treating complications. Treatment includes medications, devices like biventricular pacing, and lifestyle changes for optimal patient outcomes.
Area of Science:
- Cardiology
- Heart Failure Management
Background:
- Dilated cardiomyopathy (DCM) is a complex heart condition requiring comprehensive management.
- Effective treatment necessitates understanding hemodynamic characteristics and identifying complicating factors.
Purpose of the Study:
- To outline the diagnostic and therapeutic strategies for managing patients with dilated cardiomyopathy (DCM) heart failure.
- To detail pharmacological, interventional, and non-pharmacological approaches in DCM management.
Main Methods:
- Initial assessment includes diagnosis, hemodynamic characterization, and identification of complicating factors or surgically remedial lesions.
- Pharmacological therapy involves angiotensin-converting enzyme inhibitors, beta-blockers, digoxin, diuretics, and spironolactone.
- Advanced therapies include biventricular pacing (cardiac resynchronization therapy) and, for end-stage disease, mechanical devices and transplantation.
Main Results:
- Pharmacological agents like ACE inhibitors and beta-blockers are foundational for symptomatic DCM.
- Spironolactone shows efficacy in advanced heart failure stages.
- Cardiac resynchronization therapy is indicated for specific DCM patients with conduction defects.
Conclusions:
- A multi-faceted approach combining pharmacotherapy, device therapy, and non-pharmacological interventions is crucial for DCM management.
- Dedicated heart failure programs are essential for delivering comprehensive care, including dietary and exercise recommendations.
Abstract:
The management of patients with dilated cardiomyopathy (DCM) heart failure starts with the determination of the underlying diagnosis, definition of the hemodynamic character (eg, systolic, diastolic, valvular, right- and left-sided heart dysfunction), recognition of complicating factors (eg, atrial fibrillation, renal dysfunction), and consideration for any surgically remedial lesions (eg, severe valvular regurgitation, high-grade coronary artery occlusive disease). Angiotensin-converting enzyme inhibitors, beta-blocking agents, digoxin, and judicious diuretic administration make up the therapeutic plan for patients with symptomatic DCM heart failure. Angiotensin-converting enzymes are indicated for patients with DCM who have mild or no detectable symptoms; whether this subgroup would benefit from long-term beta-blockade remains to be established. Spirolactone also has been shown to be effective in patients with more advanced stages of heart failure. Biventricular pacing (cardiac resynchronization therapy) recently has been approved for use in patients with DCM and a left ventricular or intraventricular conduction defect and a QRS duration of longer than 140 msec. More intense pharmacotherapy, mechanical devices, and transplantation are directed at patients with severely symptomatic end-stage DCM. The effectiveness of any heart failure treatment plan is very much dependent on nonpharmacologic approaches, including dietary measures, exercise conditioning, and similar considerations, all of which are best delivered by dedicated heart failure programs.
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

